Abstract

Evidence-based chemotherapeutic management of potentially platinum‑sensitive recurrent ovarian cancer

Author(s): Maurie Markman

The results of several excellent Phase III randomized trials have helped establish appropriate management of patients with recurrent (potentially platinum sensitive) epithelial ovarian cancer. Data suggest that combination platinum-based chemotherapy is superior to single-agent platinum treatment, but the overall utility of a combination regimen versus the planned sequential administration of a platinum agent plus a second (or third) drug known to be biologically active in ovarian cancer remains to be determined. Future studies will hopefully define optimal treatment in this clinical setting more critically, including the role of therapy based on unique molecular profiles demonstrated in individual patients’ tumors.